Significantly higher levels of anti-Hsp65 antibodies in the group of patients with ovarian cancer after chemotherapy, with the mean levels of anti-Hsp60 antibodies comparable to the control group, may also indicate that protein antigenicity was modified by treatment. Here, HSPD1 is linked to ovarian cancer.